Significant Ownership of Paradigm Biocapital Advisors LP
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Paradigm Biocapital Advisors LP focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ David K. Kim - David K. Kim / Authorized Signatory
- Manager location
- New York, NY
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Paradigm Biocapital Advisors LP with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Paradigm Biocapital Advisors LP
Significant Ownership of Paradigm Biocapital Advisors LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| OLMA | Olema Pharmaceuticals, Inc. | Common Stock, $0.0001 par value per share | 10% | $37,443,949 | 7,429,355 | Paradigm BioCapital Advisors LP | 31 Dec 2024 | ||
| EWTX | Edgewise Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 9.5% | $493,917,249 | +$177,649,746 | 10,215,455 | +56% | Paradigm BioCapital Advisors LP | 30 Jun 2026 |
| ACHV | Achieve Life Sciences, Inc. | Common Stock, $0.001 par value per share | 9.2% | $29,116,913 | 9,903,712 | Paradigm BioCapital Advisors LP | 17 Apr 2026 | ||
| ASMB | Assembly Biosciences, Inc. | Common Stock, $0.001 par value per share | 7.8% | $45,012,080 | 1,553,748 | Paradigm BioCapital Advisors LP | 30 Jun 2026 | ||
| VRDN | Viridian Therapeutics, Inc. | Common Stock, $0.01 par value per share | 6.1% | $132,727,575 | +$21,516,600 | 6,723,788 | +19% | Paradigm BioCapital Advisors LP | 30 Jun 2026 |
| ASMB | Assembly Biosciences, Inc. | Common Stock, $0.001 par value per share | 5.4% | 865,251 | Paradigm BioCapital Advisors LP | 04 May 2026 | |||
| LXEO | Lexeo Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 5.3% | $19,206,757 | -$9,240,259 | 4,175,382 | -32% | Paradigm BioCapital Advisors LP | 30 Jun 2026 |
| MBX | MBX Biosciences, Inc. | Common Stock, $0.0001 par value per share | 5.2% | $78,355,461 | 2,493,015 | Paradigm BioCapital Advisors LP | 16 Jun 2026 | ||
| JBIO | Jade Biosciences, Inc. | Common Stock, $0.0001 par value per share | 5.1% | $69,032,630 | 3,106,793 | Paradigm BioCapital Advisors LP | 10 Jul 2026 | ||
| AGIO | Agios Pharmaceuticals, Inc. | Common Stock, $0.001 par value per share | 4.9% | $115,344,498 | -$6,198,499 | 2,873,555 | -5.1% | Paradigm BioCapital Advisors LP | 30 Sep 2025 |
| JANX | Janux Therapeutics, Inc. | Common Stock, $0.001 par value per share | 4.9% | $73,444,489 | -$14,982,559 | 2,920,258 | -17% | Paradigm BioCapital Advisors LP | 30 Jun 2025 |
| VOR | VOR Biopharma Inc. | Common Stock, $0.0001 par value per share | 4.5% | $23,730,000 | 1,750,000 | 0% | Paradigm BioCapital Advisors LP | 31 Dec 2025 | |
| LENZ | LENZ Therapeutics, Inc. | Common Stock, $0.00001 par value per share | 3.8% | $50,001,813 | -$16,133,961 | 1,073,461 | -24% | Paradigm BioCapital Advisors LP | 30 Sep 2025 |
| EYPT | EyePoint, Inc. | Common Stock, $0.001 par value per share | 3.8% | $44,591,181 | -$14,897,003 | 3,142,437 | -25% | Paradigm BioCapital Advisors LP | 31 Mar 2026 |
| IRON | Disc Medicine, Inc. | Common Stock, $0.0001 par value per share | 3.5% | $57,097,283 | 1,210,971 | Paradigm BioCapital Advisors LP | 31 Mar 2025 | ||
| URGN | UroGen Pharma Ltd. | Ordinary Shares, par value NIS 0.01 per share | 3.5% | $34,556,086 | -$50,946,098 | 1,703,949 | -60% | Paradigm BioCapital Advisors LP | 31 Mar 2026 |
| ERAS | Erasca, Inc. | Common Stock, $0.0001 par value per share | 3.3% | $180,417,307 | -$82,744,582 | 10,392,702 | -31% | Paradigm BioCapital Advisors LP | 31 Mar 2026 |
| CDTX | Cidara Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 3.3% | $92,041,065 | -$16,034,916 | 961,164 | -15% | Paradigm BioCapital Advisors LP | 30 Sep 2025 |
| COGT | Cogent Biosciences, Inc. | Common Stock, $0.001 par value per share | 2.3% | $45,325,875 | -$103,335,292 | 3,156,398 | -70% | Paradigm BioCapital Advisors LP | 30 Sep 2025 |
| ACLX | Arcellx, Inc. | Common Stock, $0.001 par value per share | 0% | $0 | -$656,573,828 | 0 | -100% | Paradigm BioCapital Advisors LP | 30 Jun 2026 |
| MRUS | Merus N.V. | Common Shares, (euro)0.09 nominal value per share | 0% | $0 | -$420,639,300 | 0 | -100% | Paradigm BioCapital Advisors LP | 31 Dec 2025 |
| YMAB | Y-mAbs Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 0% | $0 | 0 | Paradigm BioCapital Advisors LP | 30 Sep 2025 | ||
| MAZE | Maze Therapeutics, Inc. | Common Stock, $0.001 par value per share | 0% | $0 | -$98,702,664 | 0 | -100% | Paradigm BioCapital Advisors LP | 30 Jun 2026 |
| KURA | Kura Oncology, Inc. | Common Stock, $0.0001 par value per share | 0% | $0 | 0 | Paradigm BioCapital Advisors LP | 31 Dec 2024 | ||
| PLRX | Pliant Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 0% | $0 | 0 | Paradigm BioCapital Advisors LP | 31 Mar 2025 |
Schedules 13D/G Reported by Paradigm Biocapital Advisors LP:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.